| Literature DB >> 30773720 |
Lei Han1, Chaoyong Liu1,2, Hongzhao Qi3, Junhu Zhou1, Jing Wen4, Di Wu5, Duo Xu5, Meng Qin2, Jie Ren5, Qixue Wang1, Lixia Long3, Yang Liu6, Irvin Chen4, Xubo Yuan3, Yunfeng Lu5, Chunsheng Kang1.
Abstract
As an essential component of immunotherapy, monoclonal antibodies (mAbs) have emerged as a class of powerful therapeutics for treatment of a broad range of diseases. For central nervous system (CNS) diseases, however, the efficacy remains limited due to their inability to enter the CNS. A platform technology is reported here that enables effective delivery of mAbs to the CNS for brain tumor therapy. This is achieved by encapsulating the mAbs within nanocapsules that contain choline and acetylcholine analogues; such analogues facilitate the penetration of the nanocapsules through the brain-blood barrier and the delivery of mAbs to tumor sites. This platform technology uncages the therapeutic power of mAbs for various CNS diseases that remain poorly treated.Entities:
Keywords: blood-brain barrier; brain tumors; central nervous system diseases; monoclonal antibodies; nanomedicine
Mesh：
Substances：
Year: 2019 PMID： 30773720 DOI： 10.1002/adma.201805697
Source DB: PubMed Journal: Adv Mater ISSN： 0935-9648 Impact factor: 30.849